Prema Maria Mertz

Array ( [id] => 20129170 [patent_doc_number] => 12371472 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Multimeric IL-15 soluble fusion molecules and methods of making and using same [patent_app_type] => utility [patent_app_number] => 18/498430 [patent_app_country] => US [patent_app_date] => 2023-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 113 [patent_figures_cnt] => 183 [patent_no_of_words] => 43728 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18498430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202858 [patent_doc_number] => 20240174757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => CD131 BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/497461 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248764 [patent_doc_number] => 20240199751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST [patent_app_type] => utility [patent_app_number] => 18/495182 [patent_app_country] => US [patent_app_date] => 2023-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18495182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067287 [patent_doc_number] => 20240101713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Bi-Specific Fusion Proteins [patent_app_type] => utility [patent_app_number] => 18/483308 [patent_app_country] => US [patent_app_date] => 2023-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18483308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213582 [patent_doc_number] => 12410224 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => IL-15-based fusions to IL-7 and IL-21 [patent_app_type] => utility [patent_app_number] => 18/472053 [patent_app_country] => US [patent_app_date] => 2023-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 87 [patent_no_of_words] => 29079 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879127 [patent_doc_number] => 20240002496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIA [patent_app_type] => utility [patent_app_number] => 18/244459 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16573 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18244459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343146 [patent_doc_number] => 12466868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Engineered proteins to enhance sensitivity of a cell to IL-2 [patent_app_type] => utility [patent_app_number] => 18/460452 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 16586 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172546 [patent_doc_number] => 20240158520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/459292 [patent_app_country] => US [patent_app_date] => 2023-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28074 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902999 [patent_doc_number] => 20240018484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS [patent_app_type] => utility [patent_app_number] => 18/452952 [patent_app_country] => US [patent_app_date] => 2023-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18452952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18815955 [patent_doc_number] => 20230390294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE [patent_app_type] => utility [patent_app_number] => 18/235679 [patent_app_country] => US [patent_app_date] => 2023-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18235679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20453065 [patent_doc_number] => 12516115 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Composition for prophylaxis or treatment of IL-8 related diseases [patent_app_type] => utility [patent_app_number] => 18/450863 [patent_app_country] => US [patent_app_date] => 2023-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 48 [patent_no_of_words] => 54028 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18450863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020222 [patent_doc_number] => 20240076393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/449598 [patent_app_country] => US [patent_app_date] => 2023-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18449598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806905 [patent_doc_number] => 20230381238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/354866 [patent_app_country] => US [patent_app_date] => 2023-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 618 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18354866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389473 [patent_doc_number] => 20240279343 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/351184 [patent_app_country] => US [patent_app_date] => 2023-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59343 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18351184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739593 [patent_doc_number] => 20230348550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => IMMUNOSTIMULATING IL-2 ANALOGS [patent_app_type] => utility [patent_app_number] => 18/349656 [patent_app_country] => US [patent_app_date] => 2023-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216261 [patent_doc_number] => 20240180965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => KINASE MUTANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/348175 [patent_app_country] => US [patent_app_date] => 2023-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18348175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739592 [patent_doc_number] => 20230348549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => CYTOKINE FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS [patent_app_type] => utility [patent_app_number] => 18/346250 [patent_app_country] => US [patent_app_date] => 2023-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -120 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18346250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19955324 [patent_doc_number] => 12325731 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-10 [patent_title] => HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use [patent_app_type] => utility [patent_app_number] => 18/344242 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19961 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19242026 [patent_doc_number] => 12012445 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-18 [patent_title] => Anti-VEGF protein compositions and methods for producing the same [patent_app_type] => utility [patent_app_number] => 18/214282 [patent_app_country] => US [patent_app_date] => 2023-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 96 [patent_no_of_words] => 67555 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18214282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725895 [patent_doc_number] => 20230340134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION [patent_app_type] => utility [patent_app_number] => 18/335789 [patent_app_country] => US [patent_app_date] => 2023-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7378 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335789 [rel_patent_id] =>[rel_patent_doc_number] =>)